Fujian Haixi Pharmaceuticals Announces Major Clinical Progress for Oral wAMD Drug HXP056

Fujian Haixi Pharmaceuticals Co., Ltd. (Stock Code: 2637) has issued a voluntary announcement detailing significant progress in the development of its innovative drug, HXP056, which could become the world’s first oral therapy for hemorrhage-related retinal diseases, including wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).

Key Highlights for Investors

• Completion of Phase I Enrollment: All patient enrollments for both the single ascending dose (SAD) and multiple ascending dose (MAD) parts of the Phase I clinical trial for HXP056 have been completed. This includes dose-limiting toxicity (DLT) evaluation and pharmacokinetic (PK) data collection after four weeks of continuous dosing.
• Phase II Study Initiated: A Phase II dose expansion clinical trial has already begun in China as of Q4 2025, even as Phase I dose escalation was ongoing.
• Positive Preliminary Results: Early data from Phase I shows HXP056 has favorable safety and tolerability, with initial improvements in both fundus morphology and retinal function among treatment-naive and previously treated wAMD patients.
• Innovative Platform: HXP056 is developed using the company’s proprietary MultiSel-Opt Platform, which leverages a multi-selective mechanism for inflammation and immune regulation. It is designed to achieve optimal penetration of the blood-retinal barrier (BRB) and optimize systemic exposure, thus maximizing safety and efficacy.
• Potential Market Impact: If successful, HXP056 would be a groundbreaking advancement in retinal disease treatment, with explosive global market potential as the first oral therapy for these conditions.

Investor-Relevant Details & Potential Price Sensitivities

• Technical Milestone: The completion of Phase I and initiation of Phase II are major milestones, indicating robust progress and de-risking of the clinical development pipeline.
• Market Leadership: HXP056’s potential to be the world’s first oral therapy for retinal diseases could position Fujian Haixi Pharmaceuticals as a leader in this therapeutic area, attracting global attention and possibly partnership or acquisition interest.
• Regulatory Risks: The company reminds shareholders that, per PRC regulations, all drugs must complete clinical trials and receive approval from the National Medical Products Administration before commercialization. This process is lengthy, costly, and subject to uncertainties.
• Development Risks: Pharmaceutical development is characterized by high technology content, high risk, and high value-added. The outcome of clinical studies is uncertain and could impact share value significantly.
• Ongoing Updates: Fujian Haixi Pharmaceuticals commits to keeping investors informed of further developments in accordance with regulatory requirements.

Board Statement & Management

The announcement was made by Dr. Kang Xinshan, Chairman and Executive Director, with the support of the board comprising both executive and independent directors. The company stresses its commitment to advancing research and complying with relevant rules and regulations.

What Investors Should Watch

• Further data from Phase II and eventual Phase III studies, especially regarding efficacy and safety.
• Regulatory updates from the National Medical Products Administration.
• Potential partnering, licensing, or acquisition activity if HXP056 continues to show strong promise.
• Any delays or setbacks in clinical development or regulatory approval processes.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. The clinical development of pharmaceutical products is subject to significant risks and uncertainties. Investors should exercise caution and consult professional advisors before making investment decisions. The process from clinical trial to commercialization is lengthy, expensive, and subject to factors beyond the company’s control. Future updates will be provided as per regulatory requirements.

View HAIXI PHARMA Historical chart here